Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

NCT01625741 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Stopped by Principal Investigator decision

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Rituximab

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain